Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Klaus A. Hollmig
Observed names:
K A Hollmig,
K Hollmig,
K. A. Hollmig,
K. Hollmig,
K.A. Hollmig,
Klaus Hollmig
show all 6
Observed institutions:
University of Arkansas Medical Center,
University of Alabama at Birmingham,
Cancer Research And Biostatistics,
Heinrich Heine University Düsseldorf,
University of Arkansas for Medical Sciences
OpenAlex ID:
A5083620756
The molecular classification of multiple myeloma
2006
·
Fenghuang Zhan
, Yongsheng Huang
, et al.
·
Blood
·
1,135
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
2006
·
John D. Shaughnessy
, Fenghuang Zhan
, et al.
·
Blood
·
915
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
2006
·
Bart Barlogie
, Guido Tricot
, et al.
·
New England Journal of Medicine
·
739
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
2006
·
Ichiro Hanamura
, James P. Stewart
, et al.
·
Blood
·
479
Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications
2007
·
Ronald Walker
, Bart Barlogie
, et al.
·
Journal of Clinical Oncology
·
417
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis
2006
·
Fenghuang Zhan
, Bart Barlogie
, et al.
·
Blood
·
381
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
2007
·
Bart Barlogie
, Elias Anaissie
, et al.
·
British Journal of Haematology
·
331
PDF
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
2008
·
Bart Barlogie
, Mauricio Pineda-Roman
, et al.
·
Blood
·
225
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis
2007
·
Frits van Rhee
, Vanessa Bolejack
, et al.
·
Blood
·
184
Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant
2004
·
C-K Lee
, M Zangari
, et al.
·
Bone Marrow Transplantation
·
140
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies
2005
·
Bart Barlogie
, Guido Tricot
, et al.
·
Blood
·
135
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma
2008
·
Bart Barlogie
, Elias Anaissie
, et al.
·
Cancer
·
121
PDF
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
2008
·
Bart Barlogie
, Frits van Rhee
, et al.
·
Blood
·
102
Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling
2007
·
Jeffrey Haessler
, John D. Shaughnessy
, et al.
·
Clinical Cancer Research
·
101
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols
2009
·
Antje Hoering
, John Crowley
, et al.
·
Blood
·
100
Acquired factor VIII inhibitors in nonhemophilic patients
1997
·
D. Söhngen
, C. Specker
, et al.
·
Annals of Hematology
·
78
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989
2007
·
Bart Barlogie
, Guido Tricot
, et al.
·
Blood
·
74
PDF
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease
2006
·
Mauricio Pineda‐Roman
, Vanessa Bolejack
, et al.
·
British Journal of Haematology
·
66
Velcade (V)-Thalidomide (T)-Dexamethasone (D) for Advanced and Refractory Multiple Myeloma (MM): Long-Term Follow-Up of Phase I–II Trial UARK 2001-37: Superior Outcome in Patients with Normal Cytogenetics and No Prior T.
2005
·
Maurizio Zangari
, Bart Barlogie
, et al.
·
Blood
·
52
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics
2007
·
John D. Shaughnessy
, Jeffrey Haessler
, et al.
·
British Journal of Haematology
·
47
Marked Activity of Velcade Plus Thalidomide (V+T) in Advanced and Refractory Multiple Myeloma (MM).
2004
·
Maurizio Zangari
, Bart Barlogie
, et al.
·
Blood
·
34
A Gene Expression Signature of Benign Monoclonal Gammopathy Evident in Multiple Myeloma Is Linked to Good Prognosis.
2006
·
Fenghuang Zhan
, Bart Barlogie
, et al.
·
Blood
·
29
Bortezomib (Velcade™) + Adriamycin™ + Thalidomide + Dexamethasone (VATD) as an Effective Regimen in Patients with Refractory or Relapsed Multiple Myeloma (MM).
2004
·
Klaus Hollmig
, Julie Stover
, et al.
·
Blood
·
29
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival
2009
·
Bijay Nair
, John D. Shaughnessy
, et al.
·
Blood
·
22
Addition of Bortezomib (Velcade™) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM).
2004
·
Klaus Hollmig
, Julie Stover
, et al.
·
Blood
·
22
Show more works
View as search
Works count:
71
Citation count:
6,147
H-index:
23
I10-index:
33
Year
Topic
Type
